Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRYPHAENA: Pertuzumab + Trastuzumab in HER2+ Breast Cancer
NCT00976989Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2009
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of pertuzumab in HER2-positive breast cancer, sponsored by Roche. Started Nov 2009; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00976989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00976989.